Abstract: A method is provided that comprises generating a screen storage plate that contains screen solutions at a screen generation station; employing a transport mechanism to transport the screen storage plate from the screen generation station to a screen storage station; storing the screen storage plate in the screen storage station among a plurality of screen storage plates; having the screen storage station retrieve screen storage plate from among the plurality of screen storage plates stored within the screen storage station; and having a crystallization trial generation station generate crystallization trials in a crystallization plate incorporating the screen in the retrieved screen storage plate; wherein the method is performed in a single automated system.

Abstract: A crystallization system is provided comprising: a screen replicator configured to transfer screen solutions from wells of a screen storage plate into well regions of multiple crystallization plates; a trial generation station configured to generate crystallization trials in the trial zones of a crystallization plate; a transport mechanism configured to transport crystallization plates from the screen replicator to the trial generation station; and a controller having logic for causing the screen replicator to transfer the screen solutions from the screen storage plate to multiple crystallization plates, logic for causing the transport mechanism to transport the crystallization plates from the screen replicator to the trial generation station and logic for causing the trial generation station to generate crystallization trials in the crystallization plates.

Abstract: Detecting and determination of halooorganic compounds is described, which is applicable in the pharmaceutical industry, in fluorinated drug research and manufacturing; in the medical and clinical studies of the effects of fluoroorganic compounds; in the environmental and agricultural studies and screening, in the analysis of water, soils and air contaminated with fluoroorganic compounds.

Abstract: The invention provides compositions and methods for treating hyperlipidemia by administering a Microsomal Triglyceride Transfer Protein (MTP) inhibitor in combination with a Liver Fatty Acid-Binding Protein (L-FABP) inhibitor, methods of preventing the development of hepatic steatosis, methods of identifying an agent useful for treating hyperlipidemia, and methods of screening for inhibitors of MTP and L-FABP activity. Also provided are pharmaceutical compositions comprising a MTP inhibitor and a L-FABP inhibitor.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: A microfluidic method is provided that comprises: delivering a first fluid to a first lumen of a microfluidic device and a second, different fluid to a second lumen of the microfluidic device, the first and second lumens sharing a common wall which allows for diffusion between the lumens over at least a portion of the length of the lumens; and having the first and second fluids diffuse between the first and second lumens.

Abstract: A character based system and method for correcting low confidence characters from an OCR system facilitates operator review, editing and correction of character and field level data generated by an OCR system without the need for an application that is installed at the operator workstation. The system creates a data structure of OCR information and provides that information to an operator through an HTML interface that is rendered using HTML and JavaScript. The data structure includes an OCR confidence level for each character and/or field and the operator is prompted to review only those characters/fields that meet a predetermined threshold for the confidence level. The operator can use an input key (e.g., TAB or ENTER) to navigate to each character/field with a low confidence level and thereby correct or validate each low confidence character/field as appropriate.

Abstract: A crystallization system is provided that comprises a screen replicator having a transfer mechanism configured to transfer portions of different screen solutions contained in a screen storage plate to well regions of a crystallization plate; a screen storage station including a housing configured to store a plurality of screen storage plates and mechanics for retrieving a selected screen storage plate from among the plurality of screen storage plates for transport to the screen replicator; a transport mechanism configured to transport a screen storage plate retrieved by the screen storage station to the screen replicator; and a controller including logic for causing the screen storage station to retrieve the selected screen storage plate from among the plurality of screen storage plates, logic for causing the transport mechanism to transport the selected screen storage plate from the screen storage station to the screen replicator, and logic for causing the screen replicator to transfer portions of different

Abstract: A method is provided that comprises having a trial generation station generate crystallization trials in a crystallization plate transporting the crystallization plate to an imaging station; and having the imaging station take images of the crystallization trials within 30 minutes of the formation of the crystallization trials; wherein the method is performed in a single automated system.

Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.

Abstract: The present invention relates to a non-PCR (polymerase chain reaction) process, particularly a transcription-based amplification method, for amplifying and cloning sequences containing a variable domain sequence such as an immunoglobulin variable domain sequence from the immunological gene repertoire. The present invention comtemplates the expression of antibody library in either in an in vivo expression vector or in an in vitro transcription/translation system. Isolation of a gene coding for a receptor having the ability to bind a preselected ligand and receptors produced by the gene isolated by the method is also contemplated.

Abstract: The present invention relates to control of volatile emissions from a pile of composting organic material. Specifically, the present invention relates to covering the composting pile with a blanketing layer of finished compost material. The invention further relates to mixing finished compost with composting material either by itself or mixing the blanketing layer into the composting material during aeration. The invention also discloses adding additional blanketing layers of finished compost as previous layers are mixed into the composting material during aeration.

Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.

Abstract: Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained C1-12 alkyl, C2-12 aminoalkyl or C2-12 oxaalkyl, and a substituted and unsubstituted 3, 4, 5, 6, 7 or 8 membered ring, with the proviso that R3 and R4 are not both hydrogen; R5 is selected from the group consisting of a carbonyl, a substituted or unsubstituted C1-3 alkyl, a substituted or unsubstituted —C1-3 alkyl-C(O), a substituted or unsubstituted —C(O)—C1-3 alkyl, and a substituted or unsubstituted —C(O)C(O)C1-3 alkyl; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 3-12 atoms connecting the M substituent to the carbon atom alpha to the L substituent.

Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

Abstract: A facial expression recognition system that uses a face detection apparatus realizing efficient learning and high-speed detection processing based on ensemble learning when detecting an area representing a detection target and that is robust against shifts of face position included in images and capable of highly accurate expression recognition, and a learning method for the system, are provided. When learning data to be used by the face detection apparatus by Adaboost, processing to select high-performance weak hypotheses from all weak hypotheses, then generate new weak hypotheses from these high-performance weak hypotheses on the basis of statistical characteristics, and select one weak hypothesis having the highest discrimination performance from these weak hypotheses, is repeated to sequentially generate a weak hypothesis, and a final hypothesis is thus acquired.

Abstract: Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.